Hepatitis B News

 
 
  • Alert ACIP Issues 2018 Child and Adolescent Vaccine Schedule Recommendations clarify who should get a third dose of the mumps vaccine and highlight that the hepatitis B vaccine should be given to all nonpremature babies within the first 24 hours of life.
  • Hep B Reactivation Common During Direct-acting Antiviral Therapy for Hep C Hepatitis B virus (HBV) reactivation is common in patients with chronic HBV and hepatitis C virus (HCV) coinfection receiving direct-acting antiviral (DAA) therapy, according to a systematic review and meta-analysis.
  • Best Practice Testing Failed to ID Hidden HCV Infections A best practices HCV and HBV testing strategy failed to find hidden HCV infections, a study found. This approach may not work in low-prevalence countries.
  • Hepatitis B Vaccination Rates Subpar in Patients With HIV More than a third of patients with HIV infection fail to get hepatitis B virus (HBV) vaccination, despite a longstanding recommendation, report researchers from the Centers for Disease Control and Prevention (CDC) in Atlanta.
  • Elevated Liver Cancer, Death Rates With Chronic HBV Patients with immune-tolerant-phase chronic hepatitis B virus (HBV) infection, who are usually not considered for treatment, face an increased risk of hepatocellular carcinoma (HCC) and death, compared with treated immune-active-phase patients, researchers from Korea report.
  • In US, 4 out of 10 Cancers Could Be Prevented Potentially modifiable risk factors account for a large proportion of all cancer cases and cancer-related deaths in men and women living in the US.
  • Clinical Guideline on HBV Released by ACP, CDC The American College of Physicians (ACP) and Centers for Disease Control and Prevention (CDC) advise vaccination and screening of adults at risk for HBV, including those who are unvaccinated, and linkage to care for infected individuals.
  • Lab Screening of Kids Entering Foster Care May Have Low Yield Laboratory screening for infectious diseases in children entering foster care yields few results that are clinically meaningful, researchers report.
  • Alert Heplisav-B Vaccine for Hep B Finally Wins FDA Approval Rejected twice before by the agency, the new vaccine must undergo a large postmarketing study on the risk for acute myocardial infarctions and immune-mediated diseases.
  • AASLD Progress in Fatty Liver and Pediatric Liver Disease New findings on nonalcoholic steatohepatitis, pediatric liver diseases, hepatitis B, and the microbiome will be among the topics tackled at the upcoming Liver Meeting.
  • Incidence of Liver Cancer Rising in Most Areas of the World The global incidence of liver cancer has climbed by 75% over the last 25 years, but the main causes of liver cancer vary widely among geographic regions and to some extent by income.
  • ICVH Hepatitis Barriers to Care Focus of ICVH 2017 Efforts to improve screening for hepatitis C and access to treatment, especially for high-risk populations, will be in the spotlight at the upcoming International Conference on Viral Hepatitis (ICVH).
  • AAP Recommends Newborn Hepatitis B Vaccine by 24 Hours of Age The AAP recommendation endorses ACIP guidelines and reflects efforts to eliminate perinatal transmission of the virus, the authors write.
  • Alert FDA OKs 8-Week Mavyret for Hepatitis C Glecaprevir/pibrentasvir is the first HCV treatment of this duration approved for genotypes 1 through 6 in previously untreated adults without cirrhosis.
  • FDA Panel Supports Licensing Two-Dose Hep B Vaccine Concerns of a possible link with myocardial infarction remain, but benefits beat risks, the committee says. Members call for clearer design with the postmarketing study the company proposes.
  • Hepatitis Drugs More Affordable but Disease Still Deadly Prices of drugs to cure hepatitis C and to treat hepatitis B are dropping dramatically, offering affordability and hope to 325 million people living with the viral liver disease that can be fatal, the World Health Organization (WHO) said on Thursday.
  • Alert FDA Clears Pan-Genotypic Vosevi for Chronic Hepatitis C Vosevi, a combo of two previously approved drugs and newly approved voxilaprevir, is the first treatment approved for patients who have been previously treated with the direct-acting antiviral drug sofosbuvir or NS5A inhibitors.
  • Death Rate From Liver Cancer in US Now Double That in 1980s Mortality rates from liver cancer in the US are increasing faster than for any other cancer, with considerable disparities across ethnic groups.
  • Biologic Psoriasis Treatment Tied to Reactivation of Chronic HBV Psoriasis patients with chronic hepatitis B virus (HBV) infection who are treated with biologic therapies are at increased risk of viral reactivation, new research shows.
  • HBIG Plus Antivirals May Prevent HBV Reinfection After Transplant A very short course of hepatitis B immunoglobulin (HBIG) after liver transplantation, along with long-term antiviral therapy, may prevent hepatitis B virus (HBV) reinfection, a retrospective study suggests.